Dry Powder Inhalers (DPI)

Oral cannabidiol (CBD) is approved by the Food and Drug Administration (FDA) to treat patients with Dravet and Lennox-Gastaut syndromes,...

Background: The current study sought to formulate a dry powder inhalant (DPI) for pulmonary delivery of lipopolymeric nanoparticles (LPNs) consisting of cisplatin...

Inhalation drug delivery methods are attractive, noninvasive routes when rapid onset of action, minimal side effects and excellent bioavailability are...

Particle engineering via spray drying was used to develop a dry powder presentation of an adjuvanted tuberculosis vaccine candidate. This...

It is well established that currently available inhaled drug formulations are associated with extremely low lung deposition. Currently available technologies...

While the formulation of pharmaceuticals as liquids is common practice, powders are associated with enhanced stability, avoidance of the cold...

Novel inhalable and controlled release powder formulations of ciprofloxacin nanocrystals inside liposomes (CNL) were recently developed. In the present study, the storage stability of CNL...

Purpose Traditionally, α-lactose monohydrate is the carrier of choice in dry powder inhaler (DPI) formulations. Nonetheless, other sugars, such as...

GranuTools was present in 2 sessions at the #PBPWorldMeeting. Granutools highlighted the dramatic influence of electrostatic charges in pharmaceutical processes....

To develop stable and inhalable dry powder formulations with long shelf life, polyplexes consisting of siRNA and a polyethylenimine (PEI)‐based...